NR 546 Week 3 Exam V3 | NR 546
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 3
Exam) | Chamberlain University
1. Which of the following best describes the role of a partial agonist at a neurotransmitter
receptor?
A. It acts as a ‘dimmer switch,’ providing less than maximal activation compared to a full
agonist.
B. It blocks the receptor entirely, preventing any signal transduction.
C. It increases the production of the neurotransmitter in the presynaptic neuron.
D. It irreversibly binds to the receptor, causing permanent activation.
Answer: A
Rationale: A partial agonist binds to the receptor but only produces a partial physiological
response compared to a full agonist. This allows it to act as an antagonist in the presence of
high neurotransmitter levels or as an agonist in the presence of low levels. It is often
referred to as a stabilizer in psychopharmacology.
2. A patient is prescribed a medication that is a potent inhibitor of CYP2D6. Which of the
following drugs would likely have increased serum levels if co-administered?
A. Lithium
,B. St. John’s Wort
C. Tobacco smoke
D. Aripiprazole
Answer: D
Rationale: Many antipsychotics, such as aripiprazole, are metabolized by the CYP2D6
enzyme. If a CYP2D6 inhibitor is introduced, the metabolism of aripiprazole slows down,
leading to higher drug concentrations and potential toxicity. PMHNPs must monitor for
adverse effects when combining such medications.
3. What is the primary mechanism of action for Selective Serotonin Reuptake Inhibitors
(SSRIs)?
A. Inhibiting the Serotonin Transporter (SERT)
B. Increasing the breakdown of serotonin in the synapse
C. Antagonizing 5-HT2A receptors
D. Blocking the Monoamine Oxidase enzyme
Answer: A
Rationale: SSRIs work by binding to and inhibiting the serotonin transporter (SERT) on
the presynaptic neuron. This prevents the reuptake of serotonin from the synaptic cleft,
thereby increasing its availability to bind to postsynaptic receptors. This initial increase in
serotonin eventually leads to downstream therapeutic effects.
, 4. Which dopamine pathway is associated with the development of extrapyramidal
symptoms (EPS) when D2 receptors are blocked?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Tuberoinfundibular pathway
D. Nigrostriatal pathway
Answer: D
Rationale: The nigrostriatal pathway controls motor function and movement. When D2
receptors in this pathway are blocked by antipsychotics, it can lead to movement disorders
like EPS. This pathway is distinct from the mesolimbic pathway, which is targeted for its
role in psychosis.
5. How many half-lives are generally required for a drug to reach steady-state plasma
concentration?
A. 4 to 5 half-lives
B. 3 half-lives
C. 1 to 2 half-lives
D. 7 to 10 half-lives
Answer: A
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 3
Exam) | Chamberlain University
1. Which of the following best describes the role of a partial agonist at a neurotransmitter
receptor?
A. It acts as a ‘dimmer switch,’ providing less than maximal activation compared to a full
agonist.
B. It blocks the receptor entirely, preventing any signal transduction.
C. It increases the production of the neurotransmitter in the presynaptic neuron.
D. It irreversibly binds to the receptor, causing permanent activation.
Answer: A
Rationale: A partial agonist binds to the receptor but only produces a partial physiological
response compared to a full agonist. This allows it to act as an antagonist in the presence of
high neurotransmitter levels or as an agonist in the presence of low levels. It is often
referred to as a stabilizer in psychopharmacology.
2. A patient is prescribed a medication that is a potent inhibitor of CYP2D6. Which of the
following drugs would likely have increased serum levels if co-administered?
A. Lithium
,B. St. John’s Wort
C. Tobacco smoke
D. Aripiprazole
Answer: D
Rationale: Many antipsychotics, such as aripiprazole, are metabolized by the CYP2D6
enzyme. If a CYP2D6 inhibitor is introduced, the metabolism of aripiprazole slows down,
leading to higher drug concentrations and potential toxicity. PMHNPs must monitor for
adverse effects when combining such medications.
3. What is the primary mechanism of action for Selective Serotonin Reuptake Inhibitors
(SSRIs)?
A. Inhibiting the Serotonin Transporter (SERT)
B. Increasing the breakdown of serotonin in the synapse
C. Antagonizing 5-HT2A receptors
D. Blocking the Monoamine Oxidase enzyme
Answer: A
Rationale: SSRIs work by binding to and inhibiting the serotonin transporter (SERT) on
the presynaptic neuron. This prevents the reuptake of serotonin from the synaptic cleft,
thereby increasing its availability to bind to postsynaptic receptors. This initial increase in
serotonin eventually leads to downstream therapeutic effects.
, 4. Which dopamine pathway is associated with the development of extrapyramidal
symptoms (EPS) when D2 receptors are blocked?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Tuberoinfundibular pathway
D. Nigrostriatal pathway
Answer: D
Rationale: The nigrostriatal pathway controls motor function and movement. When D2
receptors in this pathway are blocked by antipsychotics, it can lead to movement disorders
like EPS. This pathway is distinct from the mesolimbic pathway, which is targeted for its
role in psychosis.
5. How many half-lives are generally required for a drug to reach steady-state plasma
concentration?
A. 4 to 5 half-lives
B. 3 half-lives
C. 1 to 2 half-lives
D. 7 to 10 half-lives
Answer: A
